--- title: "இந்தியாவில் GLP-1 சிகிச்சைக்கு யார் தகுதி?" description: "India GLP-1 eligibility—BMI threshold, comorbidity, thin-fat phenotype, doctor evaluation. Medically reviewed, CDSCO-aware guides for Indian patients. Kesho…" canonical: "https://www.kesho.health/ta/blog/who-qualifies-glp-1-india" markdown_url: "https://www.kesho.health/md/ta/blog/who-qualifies-glp-1-india" date_published: "Jun 15, 2026" date_modified: "Jun 26, 2026" author: "Dr. Ananya Mehta" language: "ta-IN" primary_keyword: "GLP-1 eligibility India" --- # இந்தியாவில் GLP-1 சிகிச்சைக்கு யார் தகுதி? > **Short answer:** India GLP-1 RA type 2 diabetes first-line insufficient (RSSDI); obesity BMI ≥27.5 kg/m² அல்லது comorbidity-உடன் ≥25 (ICMR). Obesity pharmacotherapy-க்கு முன் lifestyle trial. Contraindication, affordability, monitoring capacity physician assess—Kesho eligibility determine/guarantee இல்லை. Lab, waist, lifestyle documentation specialist visit. **Canonical HTML:** https://www.kesho.health/ta/blog/who-qualifies-glp-1-india **Markdown:** https://www.kesho.health/md/ta/blog/who-qualifies-glp-1-india *GLP-1 eligibility simple BMI checklist அல்ல. ICMR/RSSDI South Asian earlier metabolic risk—thin-fat, central obesity, young diabetes family history. Criteria doctor use—informed consultation prepare, decline why, self-diagnose/unregulated seller prescription guarantee avoid. Documentation, honest lifestyle history scale number equally important. Diabetes/obesity pathway contraindication screening, CDSCO Schedule H nationwide.* *Reviewed by Dr. Ananya Mehta, MD, DM Endocrinology. This article has been reviewed by our medical advisory team, including endocrinologists, internal medicine specialists, and cardiologists, and is based on current scientific evidence and Indian clinical guidelines. Last reviewed: June 2026.* ## Key takeaways - Type 2 diabetes indication high BMI not require—metformin/lifestyle despite HbA1c target unmet RSSDI GLP-1 RA support. - Obesity ICMR-aligned threshold BMI ≥27.5, comorbidity ≥25—Western BMI ≥30 lower. - Waist circumference (>90 cm men, >80 cm women), thin-fat phenotype South Asian BMI equally matter. - Pregnancy, MTC/MEN2 history, severe pancreatitis contraindication—BMI regardless CDSCO label. - Obesity pharmacotherapy before 3–6 month lifestyle intervention; GLP-1 cosmetic shortcut never. ## At a glance (India) | Field | Value | | --- | --- | | Obesity BMI threshold (no comorbidity) | ≥27.5 kg/m² (ICMR-aligned) | | Obesity BMI with comorbidity | ≥25 kg/m² | | Waist risk (South Asian men / women) | >90 cm / >80 cm | | Typical diabetes HbA1c trigger | >7–7.5% despite first-line care | | Lifestyle trial before obesity Rx | Usually 3–6 months | | Prescription requirement | Schedule H; CDSCO-approved products | ## In this article - Type 2 diabetes indications - Obesity and weight criteria - Indian BMI thresholds explained - Comorbidities that matter - Who may not qualify - Assessment workflow - Family history and risk - If you were declined - Self-assessment mistakes - Preparing for your assessment - Sleep apnoea and metabolic syndrome - Prediabetes pathway in India - Employer wellness programmes - Documentation for insurance appeals - Re-evaluation timelines ## Type 2 diabetes GLP-1 therapy qualify who? RSSDI clinical practice lifestyle, metformin glycaemic target achieve fail—typically HbA1c 7–7.5% above despite optimised care—GLP-1 RA important option position. Established cardiovascular disease, heart failure, chronic kidney disease, obesity, sulfonylurea hypoglycaemia risk patient particularly favour. Diabetes indication single BMI cut-off not; lean Indian type 2 diabetes patient overall cardiovascular, renal risk profile GLP-1 RA receive. Age, kidney function, concurrent medication selection influence. Type 1 diabetes, gestational diabetes specialist input without, diabetic ketoacidosis not indicated. Diabetologist/endocrinologist HbA1c trend, fasting/post-meal glucose, complication screening before class recommend. CDSCO-approved product Schedule H prescription clinical criteria clearly meet regardless. ## India obesity GLP-1 criteria? Obesity pharmacotherapy ICMR national guideline, South Asia adapted international protocol adult without comorbidity BMI ≥27.5 kg/m² medication consider threshold often. Comorbidity present BMI ≥25 kg/m². Western obesity guideline BMI ≥30 below sit—Indian lower body weight insulin resistance, fatty liver, cardiovascular risk develop. Waist circumference—South Asian men 90 cm+, women 80 cm+—BMI clinical assessment supplement. Pharmacotherapy never first-line; structured lifestyle intervention 3–6 month follow. Doctor motivation, mental health, eating disorder history, long-term therapy afford assess before prescribe. Metabolic indication without cosmetic motivation appropriate prescribing not. BMI threshold meet structured lifestyle attempt not doctor pharmacotherapy defer dietitian refer first. ### Thin-fat phenotype South Asian common pattern: apparently normal BMI high visceral fat, low muscle—early metabolic disease associate. ## Indian BMI threshold Western guideline differ why? Asian Indian phenotype (Joshi et al. literature) higher visceral adiposity, greater insulin resistance, earlier type 2 diabetes onset same BMI Caucasian compare. Chennai BMI 26 waist 92 cm European BMI 28 compare more metabolic risk. RSSDI, ICMR guideline incorporate. Clinical judgement essential: BMI 27 no comorbidity marathon vegetarian differently manage sedentary executive BMI 27 prediabetes, fatty liver. Genetic predisposition, family history, socioeconomic context population guideline fully capture individual decision factor. WHO Asian BMI cut-off expert consultation underpin; India-specific ICMR guidance most directly relevant patient document. ### BMI threshold: Western vs India-aligned guidance - Context: Pharmacotherapy without comorbidity — Western obesity cut-off: Often BMI ≥30 — India-aligned threshold: Often BMI ≥27.5 (ICMR) - Context: Pharmacotherapy with comorbidity — Western obesity cut-off: Often BMI ≥27 — India-aligned threshold: Often BMI ≥25 with comorbidity - Context: Waist circumference focus — Western obesity cut-off: Less emphasised — India-aligned threshold: Central obesity central to risk - Context: Lifestyle trial first — Western obesity cut-off: Recommended — India-aligned threshold: Required 3–6 months (ICMR) - Context: Type 2 diabetes indication — Western obesity cut-off: Glycaemic criteria — India-aligned threshold: RSSDI: after metformin if uncontrolled ### Earlier GLP-1 consideration support common comorbidity (BMI ≥25) - Comorbidity: Prediabetes / elevated HbA1c — Why it matters: Diabetes progression reduce; insulin sensitivity improve - Comorbidity: Hypertension — Why it matters: Weight loss, glycaemic control blood pressure management support - Comorbidity: Dyslipidaemia — Why it matters: GLP-1 RA triglyceride, weight-related lipid improve may - Comorbidity: NAFLD / fatty liver — Why it matters: 5–10% weight loss hepatic steatosis reduce - Comorbidity: Obstructive sleep apnoea — Why it matters: Weight reduction apnoea severity many patient improve - Comorbidity: Established cardiovascular disease — Why it matters: RSSDI high-risk diabetes patient GLP-1 RA favour ## GLP-1 therapy case strengthen comorbidity? BMI beyond metabolic condition cluster weigh. Central obesity prediabetes, multiple agent hypertension, high triglyceride, ultrasound NAFLD, obstructive sleep apnoea lifestyle alone not suffice pharmacotherapy justification add. Insulin resistance PCOS endocrine discussion frequent prompt. Premature cardiovascular disease/diabetes family history borderline number risk framing strengthen. RSSDI cardiovascular risk integration diabetes heart disease patient treatment algorithm isolated mild obesity patient earlier GLP-1 RA receive may. Lab report, imaging summary self-report alone document. ICMR obesity chronic disease complication treat—not cosmetic issue emphasise. ## Qualify not/specialist review need who? Contraindication: pregnancy, breastfeeding; MTC/MEN2 personal/family history; severe prior pancreatitis. Severe gastroparesis, active IBD, frail elderly low BMI further weight loss harmful caution. Inadequately treated eating disorder psychiatric support before appetite-suppress medicine. Prescribed monitoring commit/sustained therapy afford unable alternative counsel. First-degree relative thyroid cancer careful endocrine evaluation. Kesho patient screen/eligibility determination not—full history, examination, investigation treating physician alone decide. CDSCO product label contraindication BMI regardless legally binding. ## Frequently asked questions ### Do I qualify for GLP-1 if my BMI is 24? BMI alone below 25 rarely supports obesity indication unless significant comorbidities and central obesity exist—waist above South Asian cut-offs may still prompt discussion at 25+ with metabolic risk. Type 2 diabetes indication does not require high BMI; RSSDI supports GLP-1 RAs for uncontrolled glycaemia after first-line therapy. Your doctor assesses the full clinical picture including labs, family history, and prior lifestyle attempts. Document waist circumference, prediabetes labs, and fatty liver imaging if available to strengthen borderline cases. ### Can teenagers get GLP-1 in India? Paediatric obesity management requires specialist care. Some GLP-1 RAs have limited adolescent approvals globally; Indian practice varies. A paediatric endocrinologist must guide any decision. ### Does prediabetes alone qualify me? Prediabetes with BMI ≥25 and other risk factors may support obesity pharmacotherapy discussion after lifestyle trial per ICMR guidance. Lifestyle intervention remains first-line—structured diet and activity records strengthen your case at reassessment. Medication decisions are individualised; prediabetes alone at BMI 23 without comorbidities rarely justifies GLP-1 initiation. ### I have PCOS—am I eligible? PCOS with insulin resistance and elevated BMI often prompts GLP-1 discussion for weight and metabolic benefits. Gynaecologist and endocrinologist collaboration is recommended when fertility goals, contraception, and glucose targets intersect. PCOS alone without meeting BMI or comorbidity thresholds may not justify pharmacotherapy—lifestyle and hormonal management remain foundational per standard Indian practice. ### Can I get GLP-1 only for cosmetic weight loss? Ethical prescribing targets health-related obesity with comorbidity risk, not cosmetic goals alone per ICMR frameworks. Doctors may decline when BMI, waist, and metabolic risk do not meet criteria—even if social pressure or event deadlines create urgency. Pharmacotherapy without medical indication exposes you to unnecessary side effects and cost. Focus on documented health markers and lifestyle records rather than appearance targets alone when discussing eligibility. ### Does a normal HbA1c disqualify me? For diabetes indication, inadequate glycaemic control is usually required—normal HbA1c suggests diabetes-specific indication may not apply unless other factors warrant continued review. For obesity indication, HbA1c may be normal while waist circumference, fatty liver, or prediabetes still support pharmacotherapy discussion per ICMR. Criteria depend on the treatment goal your doctor is addressing; bring full labs, not BMI alone. ### How long must I try lifestyle changes before GLP-1 for obesity? ICMR guidance typically expects structured lifestyle intervention over three to six months before obesity pharmacotherapy, documented with weight, diet, and activity records. Type 2 diabetes pathways may intensify earlier when HbA1c remains above target despite metformin and lifestyle per RSSDI. Your doctor will clarify which pathway applies to your case. ### Does fatty liver alone qualify me for GLP-1? NAFLD strengthens obesity pharmacotherapy discussion when combined with BMI ≥25 and other metabolic risk after lifestyle trial. Fatty liver at BMI below twenty-five without diabetes typically requires individual specialist assessment—not automatic GLP-1 indication. ### Can I qualify if I already take metformin? Metformin use is common and compatible with GLP-1 initiation for type 2 diabetes when HbA1c remains above target. For obesity-only indication, metformin alone does not replace BMI and lifestyle criteria. Bring current metformin dose and glucose response data to your assessment. ### How does hypothyroidism affect GLP-1 eligibility? Hypothyroidism itself is not a contraindication if adequately treated—optimise thyroid hormone replacement before obesity or diabetes pharmacotherapy decisions. Untreated hypothyroidism can elevate weight and lipids, confounding eligibility assessment. Personal or family medullary thyroid carcinoma history is a separate contraindication from common hypothyroidism. Bring recent thyroid labs and medication doses to your specialist visit. ### Can I qualify with normal blood pressure and lipids? Yes for obesity pathway if BMI and lifestyle trial criteria are met—comorbidities strengthen but are not always mandatory at BMI ≥27.5. Diabetes pathway focuses on HbA1c and RSSDI cardiovascular criteria. Bring full metabolic labs, not BMI alone, to specialist assessment. Document prior dietitian or structured programme attendance when available. ## People also ask ### Can I get GLP-1 with BMI 23 if I have fatty liver? BMI alone below 25 rarely supports obesity pharmacotherapy. However, type 2 diabetes or prediabetes pathways may still apply if glycaemic criteria are met. Fatty liver with central obesity and strong metabolic risk may prompt discussion at BMI 25+ with comorbidities. Only your doctor can decide after full workup. ### Do I need a diabetes diagnosis to qualify? Not always. GLP-1 RAs are used for obesity in eligible adults without diabetes when ICMR BMI and comorbidity criteria are met after lifestyle trial. Conversely, type 2 diabetes patients may qualify without high BMI based on RSSDI glycaemic and cardiovascular criteria. ### Will my doctor prescribe GLP-1 for PCOS? PCOS with insulin resistance, elevated BMI, and metabolic risk often leads to GLP-1 discussion. Gynaecologist and endocrinologist collaboration is recommended. PCOS alone without meeting weight or glucose criteria may not justify pharmacotherapy. ### Can I qualify if I am prediabetic only? Prediabetes with BMI ≥25 and additional risk factors may support obesity pharmacotherapy discussion per ICMR frameworks. Lifestyle intervention remains first-line. Medication is individualised—not automatic for prediabetes alone. ### Does age affect GLP-1 eligibility in India? Adults are the primary population in CDSCO-approved labelling. Elderly frail patients with low BMI may be poor candidates due to unintended weight loss. Paediatric use requires specialist paediatric endocrinology—never adult telehealth shortcuts. ### What if my HbA1c is already normal? For obesity indication, normal HbA1c does not disqualify you if BMI and comorbidity criteria are met. For diabetes indication, inadequate glycaemic control is typically required—normal HbA1c suggests diabetes indication may not apply. ### Can corporate wellness programmes guarantee GLP-1 access? No ethical programme guarantees prescriptions. Eligibility requires medical evaluation, contraindication screening, and often documentation of prior lifestyle attempts for obesity indications. Avoid platforms promising automatic approval. ### How does kidney disease affect qualification? Mild to moderate kidney disease does not automatically exclude GLP-1 RAs and may favour them in diabetes with CKD per RSSDI. Severe renal impairment requires specialist dosing review. Bring recent creatinine and eGFR results to your appointment. ### I had bariatric surgery—can I still use GLP-1? Some post-bariatric patients with weight regain or recurrent diabetes may be candidates, but anatomy, nutrition status, and surgical history require multidisciplinary assessment. This is specialist territory—not self-requested prescribing. ### What documents speed up eligibility review? Bring recent HbA1c, fasting glucose, lipid panel, liver and kidney tests, thyroid history, weight trend records, prior diet programme documentation, medication list including supplements, and family history of thyroid cancer or pancreatitis. ### Does waist size alone qualify me for GLP-1? Waist above South Asian cut-offs (>90 cm men, >80 cm women) supports metabolic risk assessment alongside BMI but rarely qualifies alone without comorbidities or meeting ICMR BMI thresholds. Doctors integrate waist, labs, and history—not single measurements. ### Can I qualify with normal blood pressure and lipids? Yes for obesity pathway if BMI and lifestyle trial criteria are met—comorbidities strengthen but are not always mandatory at BMI ≥27.5. Diabetes pathway focuses on HbA1c and RSSDI cardiovascular criteria rather than requiring every comorbidity. ## References 1. [ICMR Expert Group. (2024). National Guidelines for Obesity Management in India.](https://www.icmr.gov.in/) 2. [RSSDI Clinical Practice Recommendations for Management of Type 2 Diabetes Mellitus (2023).](https://rssdi.in/) 3. [Joshi SR, et al. (2012). The Asian Indian Phenotype. JAPI, 60(Suppl), 5-8.](https://pubmed.ncbi.nlm.nih.gov/23165626/) 4. [WHO Expert Consultation. (2004). Appropriate BMI for Asian Populations.](https://pubmed.ncbi.nlm.nih.gov/14749299/) 5. [CDSCO. Drug Alerts and Advisories on GLP-1 Receptor Agonists.](https://cdsco.gov.in/) ## Related guides - [glp-1-explained-india](https://www.kesho.health/blog/glp-1-explained-india) · [MD](https://www.kesho.health/md/blog/glp-1-explained-india) - [how-to-talk-to-doctor-glp-1-india](https://www.kesho.health/blog/how-to-talk-to-doctor-glp-1-india) · [MD](https://www.kesho.health/md/blog/how-to-talk-to-doctor-glp-1-india) - [semaglutide-india-complete-guide](https://www.kesho.health/blog/semaglutide-india-complete-guide) · [MD](https://www.kesho.health/md/blog/semaglutide-india-complete-guide) - [glp-1-vs-bariatric-surgery-india](https://www.kesho.health/blog/glp-1-vs-bariatric-surgery-india) · [MD](https://www.kesho.health/md/blog/glp-1-vs-bariatric-surgery-india) --- *Kesho provides GLP-1 education only. We do not prescribe or sell medications. [Editorial policy](https://www.kesho.health/editorial-policy).*